Aemetis Q2: Operating Income Turns Positive for the First Time Since 2021, and Still Does Not Cover the Interest

Results vs. Consensus

Aemetis reported before the open on August 6. There is no company guidance to score against; the Street's published estimates for a company this size are thin and inconsistently constructed, so the beat-and-miss table below is directional rather than precise.

Year-over-year comparison

Sequential comparison

Sequential figures for Q1 2026 are the first-half totals less the reported second quarter, which is how the company's own interim filings resolve.

Revenue

The $62.7M print missed the roughly $68.3M the Street had modelled by about 8%, and the miss is best read as two unrelated things stacked on each other. Sell-side models have never settled on where 45Z income belongs or in which quarter it lands, so part of the gap is a modelling convention rather than a business shortfall. The other part is real: India shipped 1.4 thousand metric tons of biodiesel against 9.4 thousand a year ago, running the Kakinada plant at 3.6% of nameplate. That is a tender-timing hole, and management announced an allocation of more than 18 million liters worth roughly $17M on August 4, two days before the print, which should refill it in the third quarter. But a plant running at 3.6% of capacity is burning fixed cost regardless of why.

Underneath, the California operating detail is the strongest of our coverage period. Keyes ran at 113% of nameplate capacity against 100% a year ago, selling 15.5 million gallons at $2.19 versus 13.8 million at $2.01, while delivered corn fell to $6.07 a bushel from $6.42. Volume up, price up, feedstock down: all three legs of the ethanol crush moved the right way at once, which is not a common configuration. Dairy RNG sold 146.9 thousand MMBtu, up 38%, and monetized 27.5 thousand LCFS credits at $66 against 14.0 thousand at $55.

Margins

Gross margin of 21.6% against negative 6.4% is a 2,798 basis point swing, and roughly two-thirds of it is the 45Z recognition. The remaining third is operational and durable: cheaper corn, better throughput, a richer LCFS realization on approved pathways. SG&A rose only $0.4M to $7.7M on compensation incentives, so essentially the entire gross-profit swing dropped to the operating line. Operating margin of 9.2% is the first positive figure since the fourth quarter of 2021.

The honest caveat is that 45Z is not a margin the business earns from customers. It is a federal production credit whose per-unit value is set by an emissions rate the Department of Energy has not yet published, which means the largest single contributor to this quarter's margin is also the least controllable. That cuts both ways: management believes the rate is far too low and will be revised upward. It has believed that for five quarters.

EPS and the share count

The $(0.13) loss beat the roughly $(0.29) consensus by $0.16, and the improvement from $(0.41) is genuine at the operating line. But note the denominator. Weighted average shares rose 22.9% year over year, to 70.9 million from 57.7 million, and 72.0 million were outstanding at quarter-end. The company sold 2.6 million shares for $7.1M net through its at-the-market program in the second quarter alone, and the going-concern note states plainly that it expects to keep doing so. Per-share loss improved by $0.28 while the share count expanded by nearly a quarter. On an unchanged share count the loss per share would have been meaningfully better still, which is the arithmetic cost of funding operations from the equity market at these prices.

Segment Performance

The line worth staring at is segment net income. All three operating segments produced positive EBITDA, and all three still produced a net loss or a rounding-error profit, because $13.7M of interest and debt amortization sits on top. California Ethanol generated $8.4M of EBITDA and lost $1.5M after $8.9M of interest. Dairy RNG generated $3.7M of EBITDA and lost $0.2M after $1.1M of interest plus $1.5M of preferred accretion. The operating businesses work. The financing on top of them does not.

Key operating metrics

The RNG price per MMBtu falling 45% looks alarming and is not. That line is the natural gas molecule alone. The environmental attributes attached to the same molecule are reported separately as RINs and LCFS credits, both of which grew sharply in volume, and the 45Z credit is a third stream on top. Management's four-revenue-stream framing is the right way to read the segment, and on that basis Dairy RNG revenue grew 140% with a 54.5% gross margin.

California Ethanol

The strongest quarter Keyes has posted in our coverage period. Running above nameplate at 113% while corn fell 5.5% and ethanol rose 9% produced $8.9M of gross profit against a $3.8M loss a year ago, and that is before the two projects management is pointing at for 2027. Ex-45Z the segment still grew 24.3% and would have been comfortably gross-profit positive. The corn oil expansion is two of three units live with the third due this fall, together roughly doubling corn oil production against the first-quarter rate, and distillers corn oil sells into a renewable diesel and sustainable aviation fuel feedstock market management describes as strengthening on higher federal volume obligations.

"Our focus on significantly improving cash flow from our California Ethanol segment is underway with the expansion of corn oil production and ongoing construction of the mechanical vapor recompression project, which uses on-site solar and local grid electricity to replace approximately 80% of the fossil natural gas used at the Keyes ethanol plant."
— Eric McAfee, Chairman and CEO

Assessment: This is the segment where the thesis is actually being proven, and it is being proven on operations rather than on policy. A plant running above nameplate into a favourable crush with a fully funded efficiency project four months from commissioning is a good asset. The problem is that it carries $8.9M of quarterly interest against $8.4M of quarterly EBITDA, so even at this level of performance the segment does not fund itself.

California Dairy Renewable Natural Gas

Revenue up 140% to $7.3M on a 38% volume increase, with LCFS credits sold nearly doubling at a 20% higher realized price as the seven CARB-approved provisional pathways at an average negative 380 carbon intensity replace the negative 150 default. Six more pathways are in the CARB queue. The company operates twelve digesters taking waste from fifteen dairies, has more than fifty dairies under contract, expects two more digesters commissioned in the third quarter, and has received ten of the fifteen cleanup and compression units for the next tranche.

"The approval of 7 biogas digesters has been providing additional revenue at the higher LCFS value each quarter since Q3 2025 and 6 additional biogas digester pathways are nearing approval. These LCFS pathway approvals substantially expand the LCFS credit generation per MMBtu of RNG produced and will continue to drive meaningful revenue increases as we scale production."
— Eric McAfee, Chairman and CEO

Assessment: A 54.5% gross margin on a growing volume base with a visible pathway queue is the best business in the company by a wide margin, and it is the one asset that could be financed or sold on its own merits. It is also pledged. The Aemetis Biogas Series A preferred units, carried at $130.2M, are secured on all of the segment's assets, which the filing puts at $129.5M. The crown jewel is fully encumbered by an obligation larger than the assets backing it.

India Biodiesel

Revenue collapsed 78.9% to $2.5M as the oil marketing companies ran a tender process that did not conclude until late July, leaving the Kakinada plant at 3.6% of nameplate against 25.2% a year ago. The segment nonetheless turned a $0.7M gross profit against a $0.4M loss, helped by refined glycerin volumes rising from 0.1 to 0.7 thousand metric tons at a price up 75%. On August 4 the company announced allocations for more than 18 million liters over three months, worth roughly $17M. Management also flagged a genuinely new channel: with Indian pump diesel repriced upward several times on crude and Russian-supply politics, private commercial customers can now buy biodiesel at a 3% to 5% discount to diesel.

"The price of diesel in India has been controlled by the government. It's a part of their policy and with the inability for Russia to supply cheap crude oil into India, the India government has been forced to push up the price of diesel several times in the last few months. As a result, commercial customers can buy from us at attractive prices that are a discount of 3% to 5% below what they have to pay for diesel at the pump."
— Eric McAfee, Chairman and CEO

Assessment: The private-customer channel is the first structurally new thing in the India story in several quarters, and it matters more than the tender because it decouples utilization from a government procurement cycle that has now whipsawed this segment three quarters running. The IPO, by contrast, slipped again and is now explicitly conditioned on Indian equity market conditions rather than on anything the company controls. Treat India as an option with a widening time value and a shrinking probability of a 2026 monetization.

Key Topics & Management Commentary

Overall Management Tone: Confident and specific on operations, and noticeably more quantitative than in prior quarters on the size of the pending 45Z revisions, where management supplied dollar ranges rather than adjectives for the first time. On the balance sheet the posture reverted to relationship narrative: the one liquidity question drew an account of a multi-day site visit by the lender's principals and a characterization of the debt cost that the same day's 10-Q does not support. The call was short, four analysts, no pushback on the financing plan, and management volunteered nothing about the preferred redemption falling due twenty-five days later.

1. The first positive operating quarter, and what actually produced it

Operating income of $5.8M against a $10.7M loss is a $16.4M swing, and management was careful to decompose it rather than claim it all. The CFO separated the credit-driven portion from the operational portion explicitly, which is more disclosure discipline than this company has shown in the past.

"Excluding 45Z Credits entirely, Q2 gross profit of $13.8 million still improved by more than $8 million year-over-year, driven by lower priced corn at $6.07 per bushel versus $6.42 per bushel, a 12% increase in ethanol volume, ethanol pricing up 9% and a significant 38% increase in RNG volume."
— Todd Waltz, Chief Financial Officer

The $8M improvement checks out against the filings: gross profit excluding 45Z was roughly $4.9M against a $3.4M loss a year ago, an $8.3M swing. The interstitial "$13.8 million" as transcribed reconciles to neither figure, since reported gross profit was $13.5M including the credits and roughly $4.9M without them. We read it as a transcription artifact and take the filings as authoritative. The $8M is the number to carry forward, because it is the part that does not depend on an agency publishing a spreadsheet.

Assessment: A genuine operating inflection, correctly framed by management, and the strongest evidence yet for the bull pillar we have carried since initiation. It is also, at $4.9M of quarterly ex-credit gross profit against $13.7M of quarterly interest, nowhere near enough on its own.

2. Three separate 45Z revisions, quantified for the first time

The most valuable disclosure on the call was management finally putting ranges on the pending Department of Energy revisions instead of describing them qualitatively. There are three, and they are independent of each other.

"We have 3 different 45Z updates we're expecting, 2 of which we have high confidence in the third of which we have moderate level of confidence."
— Eric McAfee, Chairman and CEO

The first is the dairy RNG emissions rate. The credits sold in July were valued at $15.20 per MMBtu at a negative 42 emissions rate, against a California-equivalent score management puts near negative 420. The second is the ethanol corn emissions rate, worth $6M to $24M of one-time net cash depending on the look-back period, and $6M to $12M a year ongoing. The third is credit for CO2 reuse, worth $12M to $15M a year, where the company already reuses all of the roughly 150,000 tons a year it produces through a third-party operator but receives no 45Z value for it.

"So that number in California converted into kilograms would be about a negative 420 under the federal 45Z calculator. We're currently at negative 42. We do not have good clarity on where we're going to land between negative 42 and negative 420. So I can't give a whole lot of guidance on that."
— Eric McAfee, Chairman and CEO

Against the 146.9 thousand MMBtu sold this quarter, the gap between the current rate and the negative-375 scenario management shows in its own materials is the difference between roughly $9M and roughly $44M of annualized dairy 45Z revenue. That is management's scenario, not ours, and management itself declined to guide within the range.

Assessment: High confidence that the revisions happen, no confidence on magnitude or timing, and all three run through the same agency that has now missed five straight quarters of expected publication. The value is real and large. It is also entirely outside the company's control, and the company needs it on a schedule the agency has never committed to.

3. The Series A preferred redemption falling due August 31

The Aemetis Biogas Series A preferred units were originally $30.0M of funding. Through twelve successive waivers and amendments they are now carried at $130.2M as a long-term liability, and the twelfth amendment, effective April 30 of this year, extended the mandatory redemption date to August 31, 2026 at an aggregate redemption price of $116.7M, including a $2M fee for the amendment itself. The company held $1.0M of cash at quarter-end.

The filing spells out what happens when the redemption does not occur. The units convert into a credit agreement with the holder and the senior lender, effective September 1, 2026 and maturing September 1, 2027, priced at the greater of prime plus 10% or 16%. The company applied troubled debt restructuring accounting to the amendment. All of this is in Note 11 of the 10-Q. None of it was raised in the prepared remarks or in Q&A.

Assessment: This is the largest near-dated obligation the company faces, and it is not mentioned in the earnings release. Its practical effect is probably manageable, since the conversion mechanism is pre-agreed and the accretion already anticipates the 2027 payoff. Its analytical effect is not: it means the segment with the best margins in the company is collateral for an obligation that has quadrupled from its original principal, is now being accounted for as a troubled debt restructuring, and steps into a 16% floor rate. Any plan to finance or monetize the biogas business runs through this instrument first.

4. Interest coverage: the arithmetic that decides the equity

Adjusted EBITDA of $9.67M is the strongest quarter of our coverage period. Interest and debt amortization in the same quarter was $13.67M, and total interest expense including the preferred accretion was $15.17M. Coverage is 0.71x on the first measure and 0.64x on the second.

The first-half cash flow statement shows what that gap does in practice. Operating cash burn widened to $12.4M from $5.6M a year earlier, despite a $24.8M improvement in first-half adjusted EBITDA, because $21.3M of interest was accrued rather than paid and the 45Z receivable absorbed another $6.7M. Cash interest actually paid in the first half was $4.9M against $28.0M of interest and amortization expense: about 17%. The remainder capitalizes onto the loan balances. Total debt rose $34.1M in six months, and $26.7M of that increase, 78% of it, was accrued interest.

Assessment: This is the crux, and it is the thing that has changed most since our Q1 note. The business is now generating real EBITDA and the debt is still growing faster than the EBITDA, because the interest that is not paid in cash compounds onto principal at a weighted average stated rate near 18.2%. The company does not need the 45Z step-ups to grow; it needs them to stop the capital structure from outrunning the operations. That reframes every catalyst from upside to necessity.

5. The refinancing, a fifth quarter without a term sheet

The senior refinancing was first described as closing in late 2025, then in the first half of 2026, then as a solvency requirement at Q1. This quarter the 8-K described "advanced preparation for a potential long-term financing of the Keyes ethanol plant," and the only colour on the call came in response to a direct liquidity question.

"We have had a very positive and productive working relationship with our private credit provider, Third Eye Capital since 2018. And just within the last couple of months, had a visit by all the principals in the firm and very productive multi-day project tour and update, and we are looking forward to continued very successful relationship with Third Eye Capital."
— Eric McAfee, Chairman and CEO

The Third Eye Capital notes total $269.6M and the 10-Q states all of it is due on demand. The filing is direct about the consequence: in the event the senior lender demands repayment, the company "would likely not have sufficient cash to pay the debt when due unless we are able to obtain alternative financing." The company also obtained a waiver at June 30 for violating both the debt-to-plant-value covenant and the restrictions on capital expenditures.

Assessment: A cordial site visit is not a term sheet. The relationship has in fact been supportive for eight years and the base case remains continued accommodation, but a covenant waiver in the same quarter tightens rather than loosens the dependency. Five quarters of "in process" on the single item that determines whether the equity survives is the reason this is a Hold rather than an Outperform at a halved price.

6. Management's characterization of its own debt cost

Asked directly about liquidity and the size of current debt, the CEO offered a specific reassurance about the cost of the senior facility.

"I should note that about $120 million of our funding with Third Eye is an effective interest rate of about 5%, and then we have some more expensive debt with them as well."
— Eric McAfee, Chairman and CEO

The 10-Q filed the same day itemizes the Third Eye facilities. One tranche carries a 5% rate: the Revenue Participation Term Notes, at $12.2M. The two facilities priced at prime plus 13.75%, Revolving Notes Series B at $94.9M and the Revolving Credit Facility at $40.7M, both accrued at 20.50% at June 30 per the filing. The Acquisition Term Notes are at 17.50%, the Fuels Revolving Line at 17.75%, the Carbon Revolving Line at 15.75%, and the Term Notes at 14%.

Assessment: The $120M figure is off by an order of magnitude against the company's own filing. There is no reading of the debt note that produces $120M at 5%; the tranche at that rate is $12.2M. We do not read this as deliberate, and a slip of a decimal place under a live question is the most likely explanation. But it went uncorrected on the call, it was offered in direct response to the only question about solvency, and it made the balance sheet sound roughly two-thirds cheaper to carry than it is. Investors modelling this company from the transcript rather than the 10-Q would build a materially wrong interest forecast.

7. LCFS: a structural argument, and the price finally moving

Realized LCFS pricing rose to $66 per credit from $55, and management put spot in the $80 area against a little over $50 earlier in the year. The more interesting content was the supply-side argument for why the California deficit persists.

"There's only a certain amount of low-carbon feedstock in the market, tallow, UCO, distillers corn oil is very limited. And so you can double your renewable diesel capacity, but you're not doubling the number of LCFS credits when more soybeans and canola is used as the number of gallons increased. The second very real constraint is that over 80% of the diesel in California, about a 4 billion gallon market is already renewable diesel."
— Eric McAfee, Chairman and CEO

Management expects the deficit to widen every quarter for roughly fifteen years, against a price cap it put above $270. Separately, the company is working through registration for the Canadian Clean Fuel Regulation market, which it describes as roughly a nine-month process, and where it says gas values are meaningfully better.

Assessment: The feedstock-ceiling and vehicle-fleet-ceiling argument is the most rigorous case management has made for LCFS in the four quarters we have covered, and unlike most of what it says about policy, it does not depend on a regulator doing anything new. Realized pricing is finally confirming it. This is the one bull pillar that improved on its own merits this quarter rather than on a promise.

8. MVR: the one fully funded, near-dated catalyst

The mechanical vapour recompression project at Keyes has the key equipment on site, including six 3,500-horsepower turbofans with the final large component arriving the week of the call, foundation concrete poured, and roughly $19.7M already received in grants and Section 48C credits from the California Energy Commission, PG&E and the IRS. Management holds the end-of-2026 commissioning target and decomposed the $32M annual benefit for the first time.

"About $8 million of the $32 million, so approximately 1 quarter comes from the petroleum natural gas cost reduction every month that we have to currently endure. So we're reducing fossil natural gas by about 80%. The 45Z and LCFS value adds up to about $24 million a year."
— Eric McAfee, Chairman and CEO

Assessment: The decomposition matters because it shows only a quarter of the benefit is a hard cost saving the company controls. The other $24M is credit value, which scales with LCFS prices and with the same 45Z emissions rate the Department of Energy has not published. A fully funded project with equipment on site four months from commissioning is the most reliable item on the milestone list, but three-quarters of its stated value is still policy-contingent.

9. The at-the-market program and the dilution arithmetic

The company sold 2.6 million shares for $7.1M net in the second quarter and 5.2 million for $13.7M net in the first half, at average realized prices near $2.73 and $2.63 respectively. The going-concern note states the company has been funding operations this way and expects to continue. Shares outstanding reached 72.0 million at June 30 against 66.2 million at December 31.

Assessment: Equity issuance was about 8% of the shares outstanding at the start of the year and raised less than the quarter's capital expenditure. The problem compounds at the current price: the first-half ATM cleared near $2.63, and the stock now trades near $1.87, so raising the same dollars from here costs roughly 40% more dilution. Every quarter the catalysts slip, the funding gets more expensive in shares even if the interest rate never moves.

10. What the company did not do with the July cash

The CFO disclosed that the company received $17.6M of net cash proceeds from a 45Z credit sale on July 9, a real and welcome monetization that lands in the third quarter. The 10-Q also states that the company has "been required to remit substantially all excess cash from tax credit sales as payments of that debt."

Assessment: Read those two disclosures together and the July receipt is largely spoken for. Credit monetizations are not building a cash buffer; they are the mechanism by which the senior lender is being serviced, which is why cash fell to $1.0M from $4.9M over the half despite a $24.8M improvement in adjusted EBITDA. This is the clearest single explanation of why operating progress has not yet translated into balance-sheet progress.

Guidance & Outlook

Aemetis does not issue quarterly or annual revenue or earnings guidance, and did not start this quarter. What it provides instead is a milestone list, and this quarter, unusually, dollar ranges attached to several items. The table below is management's own framing, not our estimates.

Implied second-half shape. The third quarter should get the India tender revenue of roughly $17M spread across three months, two additional digesters, and the third corn oil unit late in the period, against no MVR contribution until 2027 and no assumed change in the 45Z rate. That points to sequential revenue growth without a step-change in credit income. The fourth quarter is where MVR commissioning and any DOE revision could both land, making it the first quarter in which the company could plausibly cover its financing cost.

Guidance style. Management has been consistently accurate on construction and operations, and consistently early on anything requiring a third party. Every project milestone it set for this quarter was met or nearly met; every policy and financing milestone slipped again. Weight the two categories differently.

Analyst Q&A Highlights

The size of the pending 45Z uplift and whether past production is recoverable

The call opened on the question that determines most of the company's near-term earnings power: how much the pending emissions-rate revision is worth, and whether it applies retroactively to molecules already produced. Management separated the three revisions and, for the first time, gave dollar ranges, while explicitly declining to guide within the widest of them.

Q: "Given the likely positive revision you'll receive in your CI score when the PER is finalized in November policy, do you have a sense of the amount of uplift you'll receive and the potential catch-up value for past molecules that have been processed under existing policy?"
— Derrick Whitfield, Texas Capital

A: "In ethanol, the corn emission rate improvement would be anywhere from $6 million to $24 million of actual net cash improvement. And that range is more defined because of the USDA calculator. What is not defined yet is exactly what periods will apply to. Treasury guidance has shown it would start January 1, 2025. And so if it does, then we'll have about an 18-month look back at a onetime recapture of that 1.5 years."
— Eric McAfee, Chairman and CEO

Assessment: The most useful exchange of the call. An 18-month look-back on the ethanol rate would be a one-time cash event of real size against a $135M market capitalization, and the ranges given are narrow enough to model. The dairy revision is the larger prize and the one management could not bound at all, describing a span between negative 42 and negative 420 with no view on where inside it the answer lands. Confidence in direction, none in magnitude.

Whether LCFS credit prices are structurally recovering

A recurring line of questioning probed the durability of the LCFS price recovery, including the effect of producers registering into the Canadian market. Management's answer was a supply-side argument rather than a forecast, and it is the most substantive case it has made on this topic.

Q: "I wanted to get your thoughts on the recovery of low carbon fuel standard credits just based on what we saw last week in the 1Q CARB report and also the proliferation of LCFS markets that we're seeing. And we're increasingly seeing some of your competitors sell into the CFR market as well."
— Derrick Whitfield, Texas Capital

A: "Technically, you see a decrease over the last 2 quarters in LCFS credits produced by renewable diesel. Also, electricity was down, renewable diesel was down. You're seeing declines in the production of LCFS credits. At the same time, as you know, every single year, the number of LCFS credits that have to be delivered has increased. So this is resulting in a larger deficit every quarter. We expect this will go on for approximately the next 15 years."
— Eric McAfee, Chairman and CEO

Assessment: This answer does not depend on a regulator doing anything new, which distinguishes it from most of the company's policy commentary. Credit supply is falling while the obligation rises annually, and realized pricing moved from $55 to $66 in the quarter with spot in the $80 area. The Canadian registration adds a second market nine months out. This is the bull pillar with the least execution risk attached.

How far LCFS pricing can run

A follow-up pressed for an upper bound on the price. Management answered with the regulatory cap and a behavioural argument about when obligated parties stop drawing down the credit bank, rather than a target.

Q: "Going back to the LCFS credit recovery, the pricing has gone from about $55 a ton to about $80 a ton recently. Do you have any guidance on how high do you think it can go?"
— Edward Woo, Ascendiant Capital

A: "Right now, I think people are relying upon the large amount of credits in the bank. But as that excess pile of credits gets rapidly depleted, I think more and more traders will look out 3 to 4 years and decide they don't want to pay $270 per credit."
— Eric McAfee, Chairman and CEO

Assessment: A cap is not a forecast, and framing the discussion around $270 invites the reader to anchor high. The useful content is the mechanism: the price moves when the bank depletes, not on a schedule. Management has been directionally right on LCFS for three quarters and repeatedly early on timing, having framed $100 for last year and then pushed $150 to 2027.

Whether India's stop-start utilization is now blocking the IPO

The India listing has been a stated objective for over a year and the plant spent this quarter at 3.6% of capacity. The question was whether the operating volatility is what is holding the offering up. Management said it is a factor but pointed primarily at the Indian equity market.

Q: "With respect to sort of the India IPO process for the India biodiesel plant, I mean, the start and stop nature of the operations over there, is that becoming a little bit of an overhang on the process, Eric? Or how should we think about that item being checked off in 2026? Or does this get pushed out to 2027?"
— Amit Dayal, H.C. Wainwright

A: "The start/stop of our operation certainly has an impact, no question at all about that. But having an equal, maybe even a stronger impact is the global increase in the price of crude oil as a result of the Iranian war... There was a bottleneck in the IPO pipeline because of the overall market price decrease that happened in the first few months or first, actually 2 quarters of 2026. That is what's directly impacting our timing."
— Eric McAfee, Chairman and CEO

Assessment: Management conceded the operating point and then relocated the blockage to a market it does not control, which conveniently removes any date it can be held to. Note also that the question offered 2027 as an option and the answer never ruled it out. The India IPO was quantified at $100M to $300M for a 20% to 25% stake three quarters ago, larger than the parent's current market capitalization. It should now be modelled as a 2027 event at the earliest.

Comfort with the liquidity position given the current debt

The only question on the balance sheet, and the closest the call came to pressure. The answer led with the lender relationship, offered the debt-cost characterization discussed above, and framed repayment as coming from future credit monetizations.

Q: "Are you comfortable with your liquidity position right now? The balance sheet seems to have quite a bit of current debt. So just wondering how you are planning to sort of address that part of the story."
— Amit Dayal, H.C. Wainwright

A: "But our goal is to continue paydowns as we do these catch-ups on 45Z and other events. So very large cash events that should be happening later on this year and that we can refinance the balance of those amounts all to longer term and lower interest rates."
— Eric McAfee, Chairman and CEO

Assessment: The plan is to pay down demand debt with credit monetizations whose timing depends on the Department of Energy, and to refinance whatever remains. That is the same plan as four quarters ago with the dates moved. Nothing in the answer addressed the $116.7M preferred redemption due 25 days after the call, and no follow-up was asked. For the one question that determines whether the equity has value, the exchange produced no new information.

Where the MVR benefit actually shows up in the margin

A question on whether the MVR project delivers more through revenue uplift or cost reduction drew the first public decomposition of the $32M figure, and it materially changes how the project should be modelled.

Q: "Expecting that you'll be entering 2027 with even stronger profile following the MVR coming online. As we're thinking through the impact of that, do you think there will be more leverage to the gross margin on the revenue gains from the MVR coming online or the cost takeouts that are also associated with that?"
— David Storms, Stonegate

A: "About $8 million of the $32 million, so approximately 1 quarter comes from the petroleum natural gas cost reduction every month that we have to currently endure... The 45Z and LCFS value adds up to about $24 million a year. As LCFS credits increase, the value of that $24 million increases."
— Eric McAfee, Chairman and CEO

Assessment: Three-quarters of the MVR benefit is credit value, not cost saving. That makes the project a leveraged bet on the same LCFS and 45Z variables the rest of the thesis already depends on, rather than the diversifying, self-help item it is usually presented as. The $8M gas saving is the only part that arrives regardless of policy.

The run-rate to expect from newly commissioned digesters

A modelling question on per-digester output produced a usable planning figure and a caveat about dairy size that has been missing from prior guidance on the buildout.

Q: "Back of the envelope math has your digesters running 40,000 to 50,000 MMBtus per year... Is that maybe a fair run rate, though, for these 2 new digesters that are coming online? Or are there other variables we should keep in mind?"
— David Storms, Stonegate

A: "The size of the dairy is the #1 criteria... But dairies in general are 25,000 to 30,000 MMBtus per year. That's what our average dairy generation is. And these dairies are approximately average dairy size."
— Eric McAfee, Chairman and CEO

Assessment: Management corrected the questioner's estimate downward by roughly 40%, which is the right instinct and a useful correction. Two average-size dairies at 25,000 to 30,000 MMBtu a year add roughly 50,000 to 60,000 MMBtu annually against the 587,000 MMBtu annualized run-rate implied by this quarter, so roughly 8% to 10% volume growth from the Q3 commissioning. Incremental, not transformational, which is the correct way to think about the digester buildout generally.

What They're NOT Saying

1. The $116.7M preferred redemption due August 31: Disclosed in Note 11 of the 10-Q, absent from the earnings release and from the call. It is the largest near-dated obligation the company has, it converts to a 16% floor-rate loan if unmet, and it is secured on the biogas assets that are the company's best business.
2. Any figure at all for the Keyes refinancing: The 8-K says "advanced preparation for a potential long-term financing." No size, no rate, no counterparty type, no expected close. Compare that with the precision management now offers on 45Z ranges, and the asymmetry in disclosure quality between what is going well and what is not becomes hard to miss.
3. The covenant waiver: The company violated both its debt-to-plant-value ratio and its capital-expenditure restrictions at June 30 and obtained a waiver. This appears in the debt note and was not mentioned in the release or on the call, despite the fact that the same lender holds $269.6M of demand debt.
4. Why operating cash burn widened: The release leads with adjusted EBITDA of $9.7M. It does not mention that first-half operating cash flow was negative $12.4M against negative $5.6M a year earlier, nor that only 17% of accrued interest was paid in cash. The gap between the EBITDA headline and the cash reality is the most important number in the filing and appears nowhere in the release.
5. What the ATM will cost from here: The going-concern note commits to continued equity sales. The company sold at an average near $2.63 in the first half and the stock now trades near $1.87. Neither the release nor the call addressed the dilution path at the lower price.
6. A corrected figure on the debt cost: The "$120 million at about 5%" characterization stood uncorrected through the end of the call, against a filing that shows $12.2M at that rate and a weighted average near 18.2%.
7. A DOE date, for a fifth straight quarter: Management said only that it "anticipates" the Department of Energy will correct the emissions rate, and noted that the agency "has not been really open about their process either." That candour is welcome and is also an admission that the company has no visibility on the item that governs its earnings power.

Market Reaction

• Pre-print setup: AMTX closed at $1.55 on August 5, up 11.5% year to date but down 39.7% over the trailing twelve months and down 12.4% over the trailing thirty days, near the bottom of a $1.32 to $3.66 52-week closing range. The S&P 500 was up 12.8% year to date entering the print.
• Reaction session: The stock gapped up 6.5% to open at $1.65, traded between $1.58 and $1.78, and closed at $1.63, up 5.2%, on 1.3 million shares against a 1.3 million 30-day average. Volume was unremarkable. The S&P was down 0.2%.
• Since the print: The stock continued higher for two weeks, closing as high as $2.07 on August 21, up 33.5% from the pre-print level, before easing to $1.87 on August 27. That is a 20.6% gain from the pre-print close over the three weeks since.

The setup is the story here, not the reaction. AMTX entered this print having fallen 50.3% from the $3.12 close on its Q1 reaction day in May. It gave back the entire 2026 re-rating over three months while the operating numbers improved in both intervening quarters, which is an unusual divergence and tells you the market spent the summer repricing the balance sheet rather than the business.

Against that setup, a 5.2% gain on unremarkable volume is a modest response to the strongest operating quarter of our coverage period. The subsequent three-week drift to $2.07 did more work than the print day itself, which is the signature of a small-cap where the filing takes longer to read than the release. The 10-Q is where the operating detail lives, and it is also where the preferred redemption and the covenant waiver live, which may explain why the stock came back off the highs into the end of the month.

What the tape has not done is re-rate the equity toward the sell-side targets, which cluster far above the current price. At $1.87 the market is valuing the equity at roughly $135M against $415.9M of debt and a $130.2M preferred liability. That is a market pricing an option, not a business.

Street Perspective

Debate: Does a positive operating quarter change the solvency question?

Bull view: The company just posted $9.7M of adjusted EBITDA and $5.8M of operating income after years of losses, monetized $17.6M of credits in cash in July, and has three quantified 45Z revisions plus a fully funded MVR project ahead of it. A lender who has supported the business for eight years is being handed exactly the earnings trajectory that makes a long-term refinancing bankable.

Bear view: One good quarter against $269.6M of demand debt is not a solvency answer. Coverage is 0.64x in the strongest quarter this business has posted, the debt grew $34.1M in six months mostly from unpaid interest, cash fell to $1.0M, and a covenant was breached and waived in the same period. The improvement is real and roughly a third of what would be needed.

Our take: The bear has the arithmetic. A business that cannot cover its financing cost in its best quarter has not solved its solvency problem, it has demonstrated the size of it. What the quarter changes is the credibility of the path: coverage of 0.64x with $50M to $59M of quantified step-ups pending, the MVR project plus two of the three 45Z revisions, is a very different picture from 0.64x with nothing pending. The equity is a wager on those step-ups arriving before the lender's patience or the share price runs out, and that wager is now better priced than it was in May.

Debate: Is the 20% revenue growth real?

Bull view: California Ethanol and Dairy RNG grew 27.9% year over year excluding 45Z entirely, on ethanol utilization of 113% of nameplate, cheaper corn, 38% more RNG volume and nearly double the LCFS credits at a 20% higher price. The consolidated line is depressed by an India tender gap that has already been refilled with a $17M allocation.

Bear view: Consolidated revenue ex-45Z grew 3.6%, the quarter missed consensus by 8%, and the headline growth rate is an artifact of a prior-year period that contained no credit income at all. A business whose growth disappears when you remove a federal subsidy is a subsidy, not a business.

Our take: Both are describing the same numbers correctly, and the segment view settles it. The California operations grew 27.9% ex-credit with a gross-profit swing of $8.3M that owes nothing to 45Z. That is a real operating inflection. The bear's framing is right about the consolidated line and wrong to extend it to the business, though the underlying point stands: this company's earnings power is inseparable from federal and state credit regimes, and always will be.

Debate: What should the equity be worth?

Bull view: A $135M market capitalization against a business with $38.7M of annualized adjusted EBITDA, a further $50M to $59M of quantified pending step-ups from the MVR project and two of the three 45Z revisions, an India subsidiary previously framed at $100M to $300M for a minority stake, and a permitted SAF project is an obvious mispricing. Published sell-side targets average many multiples of the current price.

Bear view: Enterprise value is not $135M. Adding $415.9M of debt and the $130.2M preferred liability puts it near $680M, or roughly 17.6x annualized adjusted EBITDA for a company with a going-concern qualification. Even crediting every step-up management named, the multiple compresses only to the 7x area, which is not distressed pricing.

Our take: The bear's enterprise-value framing is the correct starting point and is the single most common error we see in bullish work on this name. On delivered numbers the equity is not cheap; on fully delivered step-ups it is reasonable rather than compelling. The sell-side targets, which range from $2.50 to $28 with an average many times the current price, have plainly not been marked to the summer de-rating and should be discounted accordingly. Our own view is that fair value sits modestly above the current price with an unusually wide two-sided distribution, and that the distribution narrows sharply on either a refinancing close or a DOE publication.

Model Update Needed

Valuation impact. Anchoring on the August 27 close of $1.87 and 72.0 million shares outstanding, the equity is capitalized near $135M. Adding $415.9M of debt and the $130.2M Series A preferred liability, less $1.0M of cash, gives an enterprise value near $680M, or roughly 17.6x the $38.7M annualized run-rate implied by this quarter's adjusted EBITDA. Layering in every step-up management quantified, the MVR at $32M, the ongoing ethanol 45Z fix at $6M to $12M and the CO2 reuse credit at $12M to $15M, would take annualized EBITDA to roughly $89M to $98M and the multiple to the 7x area. That excludes the dairy emissions-rate revision, which management could not bound and which is the largest of the four.

Read that as a range rather than a target. On what the company has actually delivered, the stock is fully valued. On full delivery of the pending policy items, it is reasonably valued with meaningful further optionality from the dairy rate, India and SAF. Neither case is a compelling entry, and both sit in front of a solvency contingency we cannot handicap. We continue to frame fair value modestly above the current price with a wide two-sided band, and we would rather re-underwrite after a refinancing closes, even at a higher price, than own the interval.

Thesis Scorecard Post-Earnings

Overall: The thesis is operationally stronger and financially weaker than it was in May, and the two moved further apart rather than converging. Bull #1 is now confirmed on evidence rather than trajectory: this is a business that makes money at the operating line. Bear #1 escalated within its existing tag, adding a covenant breach, a lower cash balance, a larger twelve-month maturity stack and a preferred redemption wall that was not disclosed outside the filing. The new fact that reframes everything is the coverage arithmetic. At 0.64x in the strongest quarter this business has posted, operations do not yet fund the balance sheet, which converts every remaining catalyst from upside into requirement.

Action: Maintaining Hold. Our Q1 downgrade rested on two legs, a re-rating that had been harvested and an unpriced solvency tail. The first leg has fully reversed: at $1.87 the stock trades below the $1.92 at which we upgraded to Outperform two quarters ago, and the valuation objection is gone. The second leg got worse. Neither of the two triggers we named, a closed refinancing or a posted DOE spreadsheet, has fired, and the quarter added a covenant waiver and a preferred redemption wall we did not previously know to price. A cheaper stock against a riskier balance sheet is a wash, and a wash is a Hold. We would upgrade on a closed long-term refinancing at a materially lower blended rate, or on a published DOE emissions rate that makes the coverage arithmetic work, and we would downgrade on a lender demand, a covenant breach left unwaived, or an equity raise done at a discount to the current price.